Omeros Q3 2022 Earnings Report
Key Takeaways
Omeros Corporation reported a net loss of $17.5 million for the third quarter of 2022. The company earned royalties of $16.5 million on net sales of OMIDRIA and sold an interest in a portion of future OMIDRIA royalty receivables for $125.0 million. The FDA denied the company's appeal regarding the biologics license application for narsoplimab in TA-TMA.
Omeros earned $16.5 million in royalties from OMIDRIA sales in Q3 2022.
Net loss for Q3 2022 was $17.5 million, or $0.28 per share.
Omeros sold an interest in future OMIDRIA royalty receivables for $125.0 million.
FDA denied the appeal of the complete response letter for narsoplimab in TA-TMA but proposed a path forward for resubmission.
Omeros
Omeros
Forward Guidance
Omeros anticipates data from clinical trials and is assessing potential next steps for narsoplimab approval, while also expecting news from other programs.